Quantifying the Impact of Axillary Surgery and Nodal Irradiation on Breast Cancer-Related Lymphedema and Local Tumor Control: Long-Term Results From a Prospective Screening Trial.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

To independently evaluate the impact of axillary surgery type and regional lymph node radiation (RLNR) on breast cancer-related lymphedema (BCRL) rates in patients with breast cancer.From 2005 to 2018, 1,815 […]

» Read more

Optimal Screening in Breast Cancer Survivors With Dense Breasts on Mammography.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management […]

» Read more

Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Most distant recurrences (DRs) in women with hormone receptor-positive breast cancer occur after 5 years from diagnosis. The Clinical Treatment Score post-5 years (CTS5) estimates DRs after 5 years of […]

» Read more

Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

To examine the association between total body irradiation (TBI) and subsequent breast cancer in women treated with blood or marrow transplantation (BMT) for hematologic malignancies.Participants were drawn from the BMT […]

» Read more

Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Young women with germline BRCA mutations have unique reproductive challenges. Pregnancy after breast cancer does not increase the risk of recurrence; however, very limited data are available in patients with […]

» Read more

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

NALA (ClinicalTrials.gov identifier: NCT01808573) is a randomized, active-controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), plus capecitabine (N+C) against lapatinib, a reversible dual TKI, plus […]

» Read more

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- or 16-fraction (fr) regimen as standard. The FAST Trial (CRUKE/04/015) evaluated normal tissue effects (NTE) and […]

» Read more

Identifying oncogenic drivers associated with increased risk of late distant recurrence in post-menopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

In postmenopausal, estrogen receptor-positive, HER2-negative (ER+/HER2-) early breast cancer, the risk for distant recurrence can extend beyond 5 years of adjuvant endocrine therapy. This study aims to identify genomic driver […]

» Read more

Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Patients with brain metastases (BM) from human epidermal growth factor receptor 2 (HER2)-positive breast cancer represent a difficult-to-treat population. Trastuzumab emtansine (T-DM1) has shown potential activity in this subset of […]

» Read more

Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Lipophilic drugs, such as taxanes, have a high affinity for adipose tissue and a resulting higher volume of distribution. Here, we reanalyzed clinical trial data to investigate whether the efficacy […]

» Read more

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Nonadherence to long-term treatments is often under-recognized by physicians and there is no gold standard for its assessment. In breast cancer, nonadherence to tamoxifen therapy after surgery constitutes a major […]

» Read more

Pathogenic Germline Mutations in DNA Repair Genes in Combination With Cancer Treatment Exposures and Risk of Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

To investigate cancer treatment plus pathogenic germline mutations (PGMs) in DNA repair genes (DRGs) for identification of childhood cancer survivors at increased risk of subsequent neoplasms (SNs).Whole-genome sequencing was performed […]

» Read more

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

The oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites of disease can be ablated. However, long-term […]

» Read more

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We […]

» Read more

Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Brain metastases are frequent in HER2-positive breast cancer. ONT-380 (tucatinib) is a potent selective inhibitor of HER2 with intracranial activity in preclinical models.This was a phase I study of tucatinib […]

» Read more

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

NCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile-driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with tumors harboring actionable aberration(s) in fibroblast growth factor receptor (FGFR) 1-3 […]

» Read more

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for extended adjuvant treatment in early-stage HER2-positive breast cancer based on the phase III ExteNET study. In that trial, in which […]

» Read more

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

The predictive value of tumor mutational burden (TMB), alone or in combination with an immune gene expression profile (GEP), for response to neoadjuvant therapy in early triple negative breast cancer […]

» Read more

Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management […]

» Read more

Partial Breast Irradiation Is the Preferred Standard of Care for a Majority of Women With Early-Stage Breast Cancer.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Click here to read the full article @ Journal of clinical oncology : official journal of the American Society of Clinical Oncology

» Read more

Whole-Breast Irradiation Is the Preferred Standard of Care for the Majority of Patients With Early-Stage Breast Cancer.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Click here to read the full article @ Journal of clinical oncology : official journal of the American Society of Clinical Oncology

» Read more

Lumpectomy Margins for Invasive Breast Cancer and Ductal Carcinoma in Situ: Current Guideline Recommendations, Their Implications, and Impact.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Click here to read the full article @ Journal of clinical oncology : official journal of the American Society of Clinical Oncology

» Read more

Breast Cancer-Related Lymphedema: Risk Factors, Screening, Management, and the Impact of Locoregional Treatment.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Click here to read the full article @ Journal of clinical oncology : official journal of the American Society of Clinical Oncology

» Read more

Accelerated Partial Breast Irradiation and Intraoperative Partial Breast Irradiation: Reducing the Burden of Effective Breast Conservation.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Click here to read the full article @ Journal of clinical oncology : official journal of the American Society of Clinical Oncology

» Read more
1 2 3 15